Breaking News

Wednesday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
FDA grants accelerated approval to NS Pharma's DMD treatment Viltepso » 14:20
08/12/20
08/12
14:20
08/12/20
14:20
SRPT

Sarepta

$158.21 /

+0.12 (+0.08%)

The U.S. Food and Drug…

The U.S. Food and Drug Administration granted accelerated approval to Viltepso injection for the treatment of Duchenne muscular dystrophy, or DMD, in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. The FDA is granting the approval to NS Pharma. "This is the second FDA-approved targeted treatment for patients with this type of mutation. Approximately 8% of patients with DMD have a mutation that is amenable to exon 53 skipping," the FDA stated. Previously, on December 12, 2019, Sarepta Therapeutics announced that the U.S. Food and Drug Administration had approved Vyondys 53, an antisense oligonucleotide from Sarepta's phosphorodiamidate morpholino oligomer platform, indicated for the treatment of Duchenne muscular dystrophy in patients with a confirmed mutation amenable to exon 53 skipping.

ShowHide Related Items >><<
SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

SRPT Sarepta
$158.21 /

+0.12 (+0.08%)

Conference/Events
Sarepta management to meet virtually with Cantor Fitzgerald » 04:55
08/12/20
08/12
04:55
08/12/20
04:55
SRPT

Sarepta

$158.09 /

-1.14 (-0.72%)

Virtual Meetings to be…

Virtual Meetings to be held on August 11-12 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

SRPT Sarepta
$158.09 /

-1.14 (-0.72%)

Tuesday
Hot Stocks
Sarepta, University of Florida collaborate for rare genetic disease therapies » 08:51
08/11/20
08/11
08:51
08/11/20
08:51
SRPT

Sarepta

$159.23 /

+0.34 (+0.21%)

Sarepta Therapeutics and…

Sarepta Therapeutics and the University of Florida announced a strategic collaboration to enable cutting-edge research for novel genetic medicines. Through the agreement, Sarepta will fund multiple research programs at the University, and will have an exclusive option to further develop any new therapeutic compounds that result from the funded research programs. Through the collaboration, currently unique to UF, funding has been allocated for four innovative projects. These projects include exploratory research in novel gene therapy vectors, next-generation capsids and gene editing technologies as well as work in new therapeutic areas in degenerative genetic diseases. The goal is to foster early relationships with experts and accelerate the scientific advancements that lead to the development of transformational precision genetic medicines for patients in need.

ShowHide Related Items >><<
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

Conference/Events
Sarepta management to meet virtually with Cantor Fitzgerald » 04:55
08/11/20
08/11
04:55
08/11/20
04:55
SRPT

Sarepta

$159.23 /

+0.34 (+0.21%)

Virtual Meetings to be…

Virtual Meetings to be held on August 11-12 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

SRPT Sarepta
$159.23 /

+0.34 (+0.21%)

Monday
Conference/Events
Sarepta management to meet virtually with Cantor Fitzgerald » 10:38
08/10/20
08/10
10:38
08/10/20
10:38
SRPT

Sarepta

$159.36 /

+0.47 (+0.30%)

Virtual Meetings to be…

Virtual Meetings to be held on August 11-12 hosted by Cantor Fitzgerald.

ShowHide Related Items >><<
SRPT Sarepta
$159.36 /

+0.47 (+0.30%)

SRPT Sarepta
$159.36 /

+0.47 (+0.30%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.36 /

+0.47 (+0.30%)

SRPT Sarepta
$159.36 /

+0.47 (+0.30%)

SRPT Sarepta
$159.36 /

+0.47 (+0.30%)

Over a week ago
Earnings
Sarepta reports Q2 EPS ($1.51), consensus ($1.76) » 16:26
08/05/20
08/05
16:26
08/05/20
16:26
SRPT

Sarepta

$159.35 /

+2.67 (+1.70%)

Reports Q2 revenue…

Reports Q2 revenue $137.36M, consensus $117.13M. "I am pleased to report that, notwithstanding the distracting nature of the COVID-19 pandemic, Sarepta has continued to serve our patient community, achieving net product sales of $111.3 million, an 18% increase over the same quarter last year. And even as the majority of our workforce continued in a work-from-home environment, we have remained on mission and productive. We have already attained or remain on track to attain our many planned 2020 milestones, have deepened and extended the three pillars of our enduring gene therapy engine, and with additional data generated this year, continue to validate our unique and differentiated approach to building a gene therapy platform. Regarding our RNA platform, in the second quarter we completed our rolling New Drug Application for our third PMO candidate, casimersen and are on track to report the proof-of-concept results for our next-generation PPMO candidate in the second half of 2020. Regarding our gene therapy engine, we announced the publication of our positive one-year results for our first study of our gene therapy SRP-9001 to treat Duchenne muscular dystrophy, announced the positive expression and safety results for our high-dose cohort of LGMD2E patients treated with SRP-9003 and positive one-year functional results for our lower dose cohort treated with SRP- 9003, and are on track to commence our commercial process trial for SRP-9001 in the second half of 2020. We made great strides in gene therapy manufacturing this quarter, having now completed GMP runs for SRP-9001 using our commercial process, and commencing GMP runs for SRP-9003, to be completed by year end. And we entered into multiple partnerships to advance the science of gene therapy, including our agreements with Dyno Therapeutics, Selecta Biosciences, Codiak Biosciences and Hansa Biopharma," said Doug Ingram, Sarepta's president and CEO.

ShowHide Related Items >><<
SRPT Sarepta
$159.35 /

+2.67 (+1.70%)

SRPT Sarepta
$159.35 /

+2.67 (+1.70%)

08/04/20 Piper Sandler
Sarepta price target lowered to $200 from $206 at Piper Sandler
07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
SRPT Sarepta
$159.35 /

+2.67 (+1.70%)

SRPT Sarepta
$159.35 /

+2.67 (+1.70%)

SRPT Sarepta
$159.35 /

+2.67 (+1.70%)

Recommendations
Sarepta price target lowered to $200 from $206 at Piper Sandler » 20:02
08/04/20
08/04
20:02
08/04/20
20:02
SRPT

Sarepta

$156.68 /

-1.67 (-1.05%)

Piper Sandler analyst…

Piper Sandler analyst Tyler Van Buren lowered the firm's price target on Sarepta to $200 from $206 and keeps an Overweight rating on the shares. The analyst fine tuned estimates ahead of the company's quarterly results tomorrow. The launch of Vyondys has been slightly impacted by COVID-19 in some locations as the first few infusions require a hospital setting for extensive monitoring, Van Buren tells investors in a research note.

ShowHide Related Items >><<
SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform at SVB Leerink
07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

SRPT Sarepta
$156.68 /

-1.67 (-1.05%)

Downgrade
Solid Biosciences downgraded to Market Perform at SVB Leerink » 07:23
07/28/20
07/28
07:23
07/28/20
07:23
SLDB

Solid Biosciences

$2.53 /

-0.34 (-11.85%)

, SRPT

Sarepta

$158.30 /

-0.39 (-0.25%)

, PFE

Pfizer

$37.59 /

-0.08 (-0.21%)

As previously reported,…

As previously reported, SVB Leerink analyst Joseph Schwartz downgraded Solid Biosciences (SLDB) to Market Perform from Outperform with a price target of $3, down from $7. While the analyst continues to see potential value in SGT-001's differentiated transgene, it is increasingly unclear whether the company will be able to convince the FDA that it is appropriate to use its AAV9 vector which may have safety issues at high doses. The continuation of the clinical hold only adds more distance between Solid Biosciences and other companies in the DMD gene therapy race including Sarepta (SRPT) and Pfizer (PFE), he contends.

ShowHide Related Items >><<
SRPT Sarepta
$158.30 /

-0.39 (-0.25%)

SLDB Solid Biosciences
$2.53 /

-0.34 (-11.85%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

SLDB Solid Biosciences
$2.53 /

-0.34 (-11.85%)

07/28/20 SVB Leerink
Solid Biosciences downgraded to Market Perform from Outperform at SVB Leerink
05/08/20 Nomura Instinet
Solid Biosciences price target lowered to $6 from $10 at Nomura Instinet
05/07/20 Evercore ISI
Solid Biosciences downgraded to In Line from Outperform at Evercore ISI
12/19/19 SVB Leerink
Solid data 'underwhelming,' SGT-001 path forward unclear, says SVB Leerink
SRPT Sarepta
$158.30 /

-0.39 (-0.25%)

07/02/20 William Blair
Sarepta's recent deals may expand eligible patient set, says William Blair
06/22/20 JPMorgan
Sarepta price target raised to $190 from $160 at JPMorgan
06/15/20 Piper Sandler
Sarepta gene therapy DMD program remains differentiated, says Piper Sandler
06/09/20 Mizuho
Sarepta price target raised to $192 from $183 at Mizuho
PFE Pfizer
$37.59 /

-0.08 (-0.21%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
07/14/20 Mizuho
IPR not likely to impact uniQure's ability to commercialize AMT-061, says Mizuho
07/13/20 Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
SRPT Sarepta
$158.30 /

-0.39 (-0.25%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

SRPT Sarepta
$158.30 /

-0.39 (-0.25%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

SRPT Sarepta
$158.30 /

-0.39 (-0.25%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

PFE Pfizer
$37.59 /

-0.08 (-0.21%)

Downgrade
Solid Biosciences downgraded to Market Perform from Outperform at SVB Leerink » 06:04
07/28/20
07/28
06:04
07/28/20
06:04
SLDB

Solid Biosciences

$2.53 /

-0.34 (-11.85%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz downgraded Solid Biosciences to Market Perform from Outperform.

ShowHide Related Items >><<
SLDB Solid Biosciences
$2.53 /

-0.34 (-11.85%)

SLDB Solid Biosciences
$2.53 /

-0.34 (-11.85%)

05/08/20 Nomura Instinet
Solid Biosciences price target lowered to $6 from $10 at Nomura Instinet
05/07/20 Evercore ISI
Solid Biosciences downgraded to In Line from Outperform at Evercore ISI
12/19/19 SVB Leerink
Solid data 'underwhelming,' SGT-001 path forward unclear, says SVB Leerink
12/18/19 Nomura Instinet
Solid Biosciences price target raised to $10 from $6 at Nomura Instinet
Hot Stocks
Solid Biosciences gets FDA notice that IGNITE DMD Phase I/II trial stays on hold » 17:53
07/24/20
07/24
17:53
07/24/20
17:53
SLDB

Solid Biosciences

$2.87 /

-0.03 (-1.03%)

Solid Biosciences…

Solid Biosciences announced that it received written communication from the FDA that the company's IGNITE DMD Phase I/II clinical trial remains on clinical hold. In November 2019, the FDA placed IGNITE DMD on clinical hold as the result of a serious adverse event that occurred in the sixth patient dosed in the trial; as previously reported the SAE has fully resolved. In April 2020, Solid provided the FDA with information and measures intended to improve patient safety and in May 2020, Solid received written communication from the FDA that the trial remained on hold. In June 2020, the company submitted a response to the FDA that provided data related to manufacturing process improvements. Today, the FDA responded by maintaining the clinical hold and requesting further manufacturing information, updated safety and efficacy data for all patients dosed, and providing direction on total viral load to be administered per patient. Solid is evaluating next steps and will provide an update as appropriate.

ShowHide Related Items >><<
SLDB Solid Biosciences
$2.87 /

-0.03 (-1.03%)

SLDB Solid Biosciences
$2.87 /

-0.03 (-1.03%)

05/08/20 Nomura Instinet
Solid Biosciences price target lowered to $6 from $10 at Nomura Instinet
05/07/20 Evercore ISI
Solid Biosciences downgraded to In Line from Outperform at Evercore ISI
12/19/19 SVB Leerink
Solid data 'underwhelming,' SGT-001 path forward unclear, says SVB Leerink
12/18/19 Nomura Instinet
Solid Biosciences price target raised to $10 from $6 at Nomura Instinet

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.